Pharmacokinetics of a sustained-release trimazosin tablet formulation.
Pharmacokinetics and bioavailability of a trimazosin sustained-release tablet (SRT) formulation (300 mg) were studied in healthy volunteers. In the first study of 12 subjects, the bioequivalence of trimazosin, 100 mg, in a standard tablet (ST) and in a capsule was demonstrated. After that, the bioavailability of one SRT (300 mg) was compared with that of the STs, (100 mg three times a day), in 19 subjects. Maximum plasma concentration (Cmax) after SRT (8.1 +/- 3.0 mg/L) was significantly lower than that observed after ST (13.5 +/- 2.3 mg/L), time to peak was strongly delayed by a factor 7, and the time when plasma concentrations were higher than half of Cmax (t Cmax/2) was longer (10.4 +/- 3.2 vs 2.3 +/- 0.6 hours, p less than 0.001). Bioavailability of the SRT (300 mg) as measured by the area under the curve (AUC00) was about 65% of the ST. At the seventh dose, after single daily doses of the SRT in 12 subjects, the mean Cmax values were not significantly higher than after the first dose (8.6 +/- 3.2 mg/L vs 7.7 +/- 2.2 mg/L), t Cmax/2 values were the same (10.4 hours), and the AUC0-24 hr was comparable to AUC00 calculated after the first dose. Steady-state plasma concentration of trimazosin was obtained rapidly. No accumulation of trimazosin or its metabolite occurred.
D000293:Adolescent; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000378:metabolism*; D001682:Biological Availability; D002214:Capsules; D003692:Delayed-Action Preparations; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D010879:Piperazines / Q000008:administration & dosage / Q000378:metabolism*; D013607:Tablets
D000959:Antihypertensive Agents; D002214:Capsules; D003692:Delayed-Action Preparations; D010879:Piperazines; D013607:Tablets; C005185:trimazosin; C040290:1-hydroxytrimazosin